News

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

Novo Nordisk slides further on US competition, new CEO concerns

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk: Catch That Falling Knife

Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
24/7 Wall St.19h

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk appoints new CEO Maziar Doustdar

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...

BofA lowers rating of Novo Nordisk after Wegovy-maker issues profit warning

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...